{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=20",
    "query": {
      "condition": "Ovary Disease",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 2268,
    "total_pages": 227,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovary+Disease&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T15:19:07.930Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05797909",
      "title": "The PCOS Challenge Study",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "PCOS Challenge: The National Polycystic Ovary Syndrome Association",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 80 Years · Female only"
      },
      "enrollment_count": 15000,
      "start_date": "2022-06-22",
      "completion_date": "2042-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-10-24T15:19:07.930Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05797909"
    },
    {
      "nct_id": "NCT00418093",
      "title": "Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 19,
      "start_date": "2006-09",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2014-06-19",
      "last_synced_at": "2026-10-24T15:19:07.930Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00418093"
    },
    {
      "nct_id": "NCT01325558",
      "title": "A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Malignant Neoplasm",
        "Malignant Solid Tumour"
      ],
      "interventions": [
        {
          "name": "ALT-836 in combination with gemcitabine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Altor BioScience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2011-05",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2016-07-15",
      "last_synced_at": "2026-10-24T15:19:07.930Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Iowa City, Iowa • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01325558"
    },
    {
      "nct_id": "NCT01815138",
      "title": "Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ovarian Hyperstimulation Syndrome"
      ],
      "interventions": [
        {
          "name": "hCG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UConn Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 39 Years · Female only"
      },
      "enrollment_count": 89,
      "start_date": "2013-03",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2018-10-26",
      "last_synced_at": "2026-10-24T15:19:07.930Z",
      "location_count": 1,
      "location_summary": "Farmington, Connecticut",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01815138"
    },
    {
      "nct_id": "NCT02922348",
      "title": "Hormone Replacement for Premature Ovarian Insufficiency",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Ovarian Insufficiency"
      ],
      "interventions": [
        {
          "name": "Hormone Replacement Therapy",
          "type": "DRUG"
        },
        {
          "name": "Combined Oral Contraceptives",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 45 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2016-03-01",
      "completion_date": "2018-12-01",
      "has_results": false,
      "last_update_posted_date": "2019-07-05",
      "last_synced_at": "2026-10-24T15:19:07.930Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02922348"
    },
    {
      "nct_id": "NCT01012817",
      "title": "Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Malignant Solid Neoplasm",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Unresectable Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Topotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Veliparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2009-11-03",
      "completion_date": "2027-03-10",
      "has_results": true,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-24T15:19:07.930Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01012817"
    },
    {
      "nct_id": "NCT04296890",
      "title": "A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "Mirvetuximab Soravtansine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunoGen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 106,
      "start_date": "2020-07-23",
      "completion_date": "2022-11-16",
      "has_results": true,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-10-24T15:19:07.930Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Duarte, California • Fresno, California + 29 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04296890"
    },
    {
      "nct_id": "NCT01118052",
      "title": "EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Carcinoma",
        "Primary Peritoneal Carcinoma",
        "Recurrent Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2010-11-01",
      "completion_date": "2016-07-16",
      "has_results": true,
      "last_update_posted_date": "2018-01-11",
      "last_synced_at": "2026-10-24T15:19:07.930Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01118052"
    },
    {
      "nct_id": "NCT00842452",
      "title": "Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Endometrial Cancer",
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Sarcoma",
        "Vaginal Cancer",
        "Vulvar Cancer"
      ],
      "interventions": [
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Steven Waggoner, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2009-02",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2013-04-05",
      "last_synced_at": "2026-10-24T15:19:07.930Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00842452"
    },
    {
      "nct_id": "NCT02349958",
      "title": "Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Peritoneal Cancer",
        "Fallopian Tube Cancer",
        "Uterine Cancer",
        "Mesotheliomas",
        "Gastrointestinal Cancers",
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "HIPEC: MMC 30mg @ T0, 10mg @ T45min",
          "type": "DEVICE"
        },
        {
          "name": "HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0",
          "type": "DEVICE"
        },
        {
          "name": "HIPEC: CDDP 75 mg/m2 @T0",
          "type": "DEVICE"
        },
        {
          "name": "HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Bay Area Gynecology Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 200,
      "start_date": "2006-09",
      "completion_date": "2022-01",
      "has_results": false,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-10-24T15:19:07.930Z",
      "location_count": 1,
      "location_summary": "Los Gatos, California",
      "locations": [
        {
          "city": "Los Gatos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02349958"
    }
  ]
}